Phase I Trial of Afatinib and Trastuzumab in HER2 Overexpressing Cancer.
Boehringer Ingelheim
Boehringer Ingelheim
Boehringer Ingelheim
OHSU Knight Cancer Institute
Cambridge University Hospitals NHS Foundation Trust
Boehringer Ingelheim
National Taiwan University Hospital
Boehringer Ingelheim
Boehringer Ingelheim
Boehringer Ingelheim
Boehringer Ingelheim